Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Scentian Bio Limited currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, which focuses the company's current legal interactions on a single official at the patent office. The prosecution is taking place within 1 distinct art unit, suggesting that the company's biological technology is classified within a specific technical division. This focused administrative structure allows for a direct and singular approach to managing the company's current intellectual property filings.
The busiest examiner for the portfolio is OGUNTADE, ELIZABETH BISOLA, who is responsible for 1 busiest examiner pending office action. Since the total number of pending office actions is also 1, this examiner is the sole person currently evaluating the company's active cases. For a practitioner, this means that the success of the current prosecution phase is entirely dependent on the decisions of this one individual. The alignment of 1 distinct examiner and 1 distinct art unit indicates a highly specialized technical focus for the company's current applications. The outcome of this 1 pending office action will be the key measure of the company's immediate progress in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNTADE, ELIZABETH BISOLA | 1 | 50.0% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18583719 | Sensor Device and Methods | OGUNTADE, ELIZABETH BISOLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18583719 | Sensor Device and Methods | OGUNTADE, ELIZABETH BISOLA | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18583719 | Sensor Device and Methods | OGUNTADE, ELIZABETH BISOLA | 1677 | §103§112Other | Non-Final OA | — | Pending | Feb 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScentian Bio Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elizabeth Bisola Oguntade has the most, with 1 of Scentian Bio Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
